Clovis Oncology, Inc. (CLVS)
(Delayed Data from NSDQ)
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.95 USD
+0.51 (2.77%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Onconova (ONTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will watch for updates on its lead candidate narazaciclib when Onconova Therapeutics. (ONTX) reports first-quarter earnings.
Viatris (VTRS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q1 earnings might have been adversely impacted by competition in the complex generics business.
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 0% and 45.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Eylea, Dupixent Buoy Regeneron's (REGN) Q1 Earnings?
by Zacks Equity Research
Regeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) is set to report earnings and revenue figures and provide updates on its pipeline when it releases first-quarter 2022 results.
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Supply shortage along with pandemic-led incremental mortality rate is likely to have weighed on DaVita's (DVA) first-quarter top line.
Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Clovis (CLVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis (CLVS) Up 24% on Upbeat Data From Ovarian Cancer Study
by Zacks Equity Research
Clovis Oncology's (CLVS) stock price rises after it reports favorable data from a late-stage study on Rubraca as the first-line maintenance treatment of ovarian cancer.
Why Is Clovis (CLVS) Down 14.8% Since Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca, Merck's Lynparza Cut Risk of Breast Cancer Death
by Zacks Equity Research
Treatment with AstraZeneca (AZN) and Merck's (MRK) Lynparza show meaningful improvement in overall survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.
AstraZeneca, Merck's Lynparza Gets FDA Nod for Expanded Use
by Zacks Equity Research
FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.
Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag
by Zacks Equity Research
Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.
Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Why Is Clovis (CLVS) Down 32% Since Last Earnings Report?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca, Merck's Lynparza sNDA Gets FDA Priority Tag
by Zacks Equity Research
FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) sNDA for Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.
Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Lag
by Zacks Equity Research
Clovis (CLVS) reports wider-than-expected loss for third-quarter 2021. Sales of the company's sole marketed drug, Rubraca, declined year over year owing to COVID-19 impacts.
Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of -16.67% and -2.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Clovis Oncology (CLVS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis (CLVS) Focuses on Rubraca Growth Amid Rising Competition
by Zacks Equity Research
Clovis Oncology's (CLVS) sole marketed drug Rubraca has been approved for multiple cancer indications. Yet, the drug's sales remain tepid on account of competition from PARP inhibitors.
Bet on Rising P/E Investing With These Top 5 Stocks
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Clovis (CLVS) Down 3.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Clovis (CLVS) Q2 Earnings Miss, PARP Drug Rubraca Sales Down
by Zacks Equity Research
Clovis (CLVS) reports wider-than-expected loss for second-quarter 2021. Sales of the company's sole marketed drug, Rubraca, decreased year over year due to COVID-19 impacts.
Clovis Oncology (CLVS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clovis (CLVS) delivered earnings and revenue surprises of -7.02% and -9.78%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.